Janiczek Wealth Management’s Amicus Therapeutics FOLD Stock Holding History

Janiczek Wealth Management’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-5,000	Closed	-$40K	–	159
2019 Q3	$40K	Hold	5,000	–	–	0.02%	73
2019 Q2	$62K	Hold	5,000	–	–	0.03%	63
2019 Q1	$68K	Hold	5,000	–	–	0.03%	68
2018 Q4	$48K	Hold	5,000	–	–	0.02%	77
2018 Q3	$60K	Hold	5,000	–	–	0.03%	63
2018 Q2	$78K	Buy	+5,000	New	+$75.6K	0.04%	59

Other funds holding FOLD

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Janiczek Wealth Management's FOLD Position: Q4 2019 in Review

Janiczek Wealth Management sold out of Amicus Therapeutics (FOLD) in Q4 2019, closing a stake of 5,000 shares — an estimated $40K sold.

Janiczek Wealth Management first reported a position in FOLD in Q2 2018 and held it in 6 quarters. The position peaked at $78K in Q2 2018. 224 funds tracked by Wall St. Rank hold FOLD as of Q4 2019.

Janiczek Wealth Management reported no remaining Amicus Therapeutics position as of Q4 2019 after selling out during the quarter.
Janiczek Wealth Management sold 5,000 Amicus Therapeutics shares in Q4 2019, an estimated $40K.
Janiczek Wealth Management first reported a position in Amicus Therapeutics in Q2 2018 and held it in 6 quarters.
Janiczek Wealth Management's Amicus Therapeutics position peaked at $78K in Q2 2018.
224 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2019.

Based on Janiczek Wealth Management's 13F filing for Q4 2019, filed 5 Feb 2020.